- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Report: Emerging Therapies Offer Efficacy Advantages Over Current Ovarian Cancer Treatments
Overall survival and delayed disease progression are key unmet needs (June 10)
Decision Resources, a research and advisory firm located in Burlington, Mass., finds that the effect of an emerging therapy on key efficacy endpoints, including time to disease progression and overall survival, has the most influence on surveyed U.S. and European oncologists’ prescribing decisions for platinum-resistant advanced ovarian cancer.
All of the emerging drugs for this indication — bevacizumab (Avastin; Roche/Genentech), which is already approved in Europe for recurrent platinum-sensitive ovarian cancer; trebananib (Amgen/Takeda); vintafolide (Merck/Endocyte); and olaparib (AstraZeneca) — are expected to offer efficacy advantages over currently available therapies used to treat platinum-resistant advanced ovarian cancer.
The report also finds that surveyed U.S. oncologists would prescribe bevacizumab in combination with either weekly paclitaxel (Taxol; Bristol-Myers Squibb; generics) or doxorubicin (Doxil/Caelyx; Janssen Biotech) to a total of 55% of their patients with platinum-resistant advanced ovarian cancer.
Further, the report finds that surveyed pharmacy directors at managed care organizations (MCOs) are receptive to novel therapies that offer improved progression-free survival (PFS) in this patient population. Based on clinical data and thought leaders’ opinions, bevacizumab in combination with chemotherapy is in position to offer the PFS benefit that most of the surveyed U.S. payers indicated would be necessary for widespread inclusion on MCO formularies.
“The platinum-resistant advanced ovarian cancer population represents a patient population with high unmet need,” said analyst Gemma McConnell, PhD. “Current treatment consists of a non-platinum chemotherapy monotherapy, which typically results in low tumor response rates and a short progression-free interval. Taking together positive phase III clinical data and interviewed experts’ opinion, Avastin in combination with chemotherapy is poised to address this unmet need.”
Source: Decision Resources; June 10, 2013.